Ohio State Navbar


Eric Kraut, MD

Staff photo

320 W 10th Ave
Columbus, OH 43210

Phone: (614) 293-2887

Email: kraut.2@osu.edu


Current OSU Appointments

Professor, Hematology

Physician, FGP-Hematology



Eric H. Kraut, MD, is Professor of Internal Medicine, Division of Hematology, at Arthur G. James Cancer Hospital & Richard Solove Research Institute at The Ohio State University in Columbus, where he also directs the Benign Hematology Program, the Sickle Cell Program, and the Thrombosis and Hemophilia Center.

Dr. Kraut received his medical degree from Temple University School of Medicine in Philadelphia, Pennsylvania. He completed an internship and residency at University of Pittsburgh in Pennsylvania and a fellowship at The Ohio State University, Division of Hematology and Oncology. He is board certificated in internal medicine, hematology, and oncology.

Dr. Kraut has authored or co-authored over 98 journals, 10 book chapters and monographs, and 92 abstracts, in addition to frequently lecturing. He is a 2012 Biographical Candidate in the “Who's Who Among Executives and Professionals, Honors Edition" Registry.

Dr. Kraut holds professional membership with the American Society of Hematology and American Society of Clinical Oncology. He also serves on multiple committees, such as the Finance Committee Department of Medicine, Adult Sickle Cell Steering Committee, ASH Teaching Cases Subcommittee, and Anticoagulation Therapy Workgroup. He is a member of the NCCN Cancer- and Chemotherapy-Induced Anemia Panel.

Academic Advising

2012 - present Korkor Sackey, The Ohio State University.
2011 Scha'Chia Murphy, The Ohio State University.


Surgical Procedures in Patients With Inhibitors To Factor VIII: A Case Series.



1975 - present Medical License: State Medical Board of Ohio
1975 - present Board Certification: American Board of Internal Medicine
1977 - present Board Certification: American Board of Internal Medicine
1978 - present Board Certification: American Board of Internal Medicine
1973 - 1975 Board Certification: Temple University

Chapters in Books

Diseases of the Spleen

Drug Regimens in the Treatment of Cancer of the Lung, Cancer of the Skin, and Cancer of the Endocrine System


Complications of Cancer and Cancer Therapy

Lymphoma’s, Otolaryngology - Head and Neck Surgery

Lymphoma’s, Otolaryngology - Head and Neck Surgery

Clinical Manifestations Complications and Infections of Hairy Cell Leukemia

Hairy Cell Leukemia - Definitions of Remission, Prognosis and



Pharmacogenomic and pharmacokinetic assessment of liposome encapsulated SN-38 (LE-SN38) in advanced cancer patients.

Severe and Prolonged Lymphopenia Observed In Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer



1968 B.A., Franklin and Marshall College

1972 M.D., Temple University


Editorial Activities

1994 - 1995 American Journal of Hematology
1998 - 1999 Investigational New Drugs
2003 - 2004 American Journal of Hematology
2003 - 2007 BLOOD
2005 Investigational New Drugs
2005 - 2008 Hematolgica
2006 BLOOD
2006 - 2007 Annals of Internal Medicine
2007 - present Haematologica
2007 Blood
2008 - present Haematologica
2008 - present BLOOD
2009 - present Cancer Chemotherapy
2009 - present Leukemia and Lymphoma
2009 - present Pharmacology


1970 Junior, Fellow. American Cancer Society.
1976 - 1977 Fellow-Ohio. American Cancer Society.
1978 - 1981 Junior Faculty Fellow. American Cancer Society.
1982 - 1983 Oustsanding Module, Med II. American Cancer Society.
2002 - 2003 Bertha Borouncle Teaching Award. Department of Hematology and Oncology.
2007 - present America's Best Doctors. U.S. News & World Report.
2008 Nominated for the 2008 Earl N. Metz Distinguished Physician Award. The Ohio State University.
2009 Earl N. Metz Distinguished Physician Award. The Ohio State University.
2010 Biographical Candidate "Who's Who Among Executives and Professionals", "Honors Edition" Registry. Who's Who in America.

Journal Articles

"Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies." JOURNAL OF CLINICAL ONCOLOGY. Vol. 20, no. 11. (June 2002.): -.

"Cancer- and chemotherapy-induced anemia.." Journal of the National Comprehensive Cancer Network : JNCCN. Vol. 6, no. 6. (July 2008.): -.


Reference Works

December 1954 ."" .
January 1977 EH Kraut, Dunlap JE, Stevenson TD and King GW."Immune Function in Successfully Treated Acute Leukemia Patients" . : Clin Res, 25:578A
January 1977 EH Kraut, Leiby JM, Metz EN, Malspeis L and Grever MR."A Prospective Comparison of Deoxycytidine Kinase Activity with Response to 2-Fluoro-Ara-Amp in Patients with Non-Hodgkin's Lymphoma" . : 66(1):215A
January 1978 EH Kraut and Sagone AL Jr."The Alternative Pathway of Complement in Multiple Myeloma" . : 19:270
January 1978 EH Kraut, Metz EN and Sagone AL Jr."In Vitro Effects of Ascorbic Acid (AA) on the Chemiluminescence of granulocytes (PMN's)" . : 25:578
January 1981 Segal ML, Fertel RH, EH Kraut, Sagone AL Jr."The Role of Reactive Oxygen Species in Thromboxane B2 Generation by Human Polymorphonuclear Leukocytes" .
January 1981 Kaiki JH, Stephens R, Leite CF EH Kraut, Fletcher W."Phase II Evaluation of Gallium Nitrate (NSC152000) in Soft Tissue and Bone Sarcomas." . : 22:525
January 1981 EH Kraut and Sagone AL Jr."The Effect of Oxygen Radical Scavengers on Polymorphonuclear Leukocyte Aggregation" . : 29:338A
January 1981 EH Kraut and Sagone AL Jr."A Role for Sulfhydryl Groups in Polymorphonuclear Leukocyte Aggregation" . : 29:338
January 1982 Hebert IA, Waxman FJ, Birmingham DJ, Cornacoff JB, Van Aman MA, Smead WL, EH Kraut.."Complement (C) Depletion Accelerates the Clearance of Immune Complexes (IC) from the Circulation of Primates" .
January 1983 EH Kraut, Grever MR, Wilson HE, Neidhart JA and Balcerzak SP."Deoxycoformycin (dCF) in the Treatment of Refractory Chronic Lymphocytic Leukemia (CLL)" .
January 1983 EH Kraut, Grever MR, Neidhart JA and Malspeis L."2-Fluoro ARA-AMP: A Phase I Clinical Investigation" .
January 1984 EH Kraut, Grever MR, Leiby JM, Neidhart JA, Malspeis L and Balcerzak SP."A Phase I Investigation of 2-Fluoro-ARA-AMP in Refractory Leukemia" . : 64(1):165A
January 1984 EH Kraut, Leiby J, Grever M, Metz E and Malspeis L."FAMP Therapy in Lymphoma" . : 64(1):182A
January 1984 E Kraut, Ehrlichman C, Robert F, Velez-Garcia E, Bender J and Grillo-Lopez A."A Phase II Trial of Diaziquone (AZQ) in Patients with Colon Cancer" . : 3:C527
January 1985 EH Kraut, Leiby JM, Metz EN, Neidhart JA, Malspeis L and Grever MR."Fludarabine Phosphate in Relapsed Non-Hodgkin's Lymphoma" . : 33:891A
January 1985 EH Kraut, Neidhart JA, Metz EN and Howenstein B."Phase I Study of Homoharringtonine (HH) Administered by Prolonged Continuous Infusion" . : 4:C188
January 1985 EH Kraut, Bouroncle BA and Grever MR."Treatment of Hairy Cell Leukemia with Low Dose 2-Deoxycoformycin" .
January 1985 Malspeis L, Balcerzak SP and Grever MR."Phase I Clinical Trial of Pibenzimol" . : 4:C143
January 1985 EH Kraut, Wenger GD, O'Dorisio MS."Characterization of cAMP-Dependent Protein Kinases During Differentiation of Normal and Leukemic Monocytes and U937 Cells" . : 33(2):357A
January 1985 EH Kraut, Grever MR, Gochnour DC, Neidhart JA."A Phase I Clinical Investigation of Acodazole" . : 26:702
January 1986 EH Kraut, Neff JC and Grever MR."Immune Function in Hairy Cell Leukemia Patients in Complete Remission after 2-Deoxycoformycin" . : 68(1):225A
January 1986 Grever MR, Leiby JM, Wilson HE, EH Kraut, Wall RW, Bouroncle BA, Metz EN, Rinehart JJ and Balcerzak SP."Deoxycoformycin in Chronic Leukemia" .
January 1986 EH Kraut, Grever MR, Gochnour DC, Neidhart JA, Balcerzak SP and Malspeis L."A Phase I Clinical Investigation of Acodazole" . : 5:53
January 1986 EH Kraut, O'Dorisio TM, Page JG and Grieshaber CK."Evaluation of the Pancreatic Toxicity of Pibenzimol (NSC 32292 1) in Dogs" . : 27:420
January 1986 EH Kraut, Grever MR, and Leiby JM."Correlation of Biochemical Parameters to Response with Deoxycoformycin (dCF) in Chronic Leukemia" . : 27:195
January 1987 EH Kraut, Bouroncle BA and Grever MR."Low Dose 2-Deoxycoformycin in the Treatment of Advanced Hairy Cell Leukemia" . : 70(1):232A
January 1987 Grever MR, McGee RA, EH Kraut, Salmon SE and Athens JW."Deoxycoformycin in Refractory Myeloma" . : 70(1):246A
January 1987 Theil KS, Bouroncle BA and Grever MR, EH Kraut.."Bone Marrow Changes in Hairy Cell Leukemia Treated with Low-Dose Deoxycoformycin" . : 70(1):239A
January 1987 Malspeis L, Staubus AE, Supko JG, Grever MR, EH Kraut.."Pharmacokinetics and Metabolism of Merbarone NSC 336628) in Patients" . : 28:906
January 1988 EH Kraut, Grever MR, Leiby JM, Balcerzak SP, Staubus AE and Malspeis L."A Phase I Investigation of Flavone Acetic Acid (NSC 347512)" . : 7:236
January 1988 EH Kraut, Malspeis L, Balcerzak SP and Grever MR."Evaluation of Pibenzimol (NSC 322921) in Refractory Solid Malignancies" . : 7:237
January 1988 EH Kraut, Grever MR, Staubus AE and Malspeis L."Phase I Clinical Trial of Merbarone (NSC 336628)" .
January 1988 Grever MR, EH Kraut, Supko JG, Trewyn RW, Staubus AE and Malspeis L."(NSC 336628) Enhances the Urinary Excretion of Uric Acid of Cancer Patients" . : 29:752
January 1988 JG, Grever MR, Balcerzak SP, EH Kraut, Staubus AE and Malspeis L."Spectral Characterization and Quantitation of the Principal Metabolites of Merbarone (NSC 336628) in the Urine of Patients" . : 29:751
January 1988 EH Kraut, Grever MR and Bouroncle BA."Deoxycoformycin (Pentostatin) in the Treatment of Hairy Cell Leukemia" .
January 1988 Leiby JM, Malspeis L, Staubus AE, Kraut EH, Grever MR."Fazarabine (NSC 281272) is Myelosuppressive at the Initial Dose Level in a Phase I Study" . : 7:235
January 1988 Leiby JM, Malspeis L, Staubus AE, EH Kraut, Grever MR."Amonafide (NSC 308847): A Clinical Phase I Study of Two Schedules of Administration" . : 29:1103
January 1989 EH Kraut, Grever MR and Salmon S."Phase II Trial of Fludarabine Phosphate in Multiple Myeloma" . : 30:1052
January 1990 Grever MR, Brager P, EH Kraut, Metz E."Phase II Trial of Deoxycoformycin in Malignant Melanoma" . : 31:A1181
January 1990 Schisler M, EH Kraut, Muller M."Variability of Topoisomerase I Levels in Leukemia Patients: A Molecular Analysis to Evaluate Clinical Response to Camptothecin" .
January 1990 Wissel M, Hazy L, Williams M, EH Kraut, Blazina J."Platelet Transfusion Responses in a Leukemia Patient with Anti-PLA1" .
January 1990 Staubus AE, Malspeis L, Baleerzak SP, Leiby JM, Kraut ER, Grever MR."Clinical Pharmacokinetics of Fazarabine (NSC 281272)" . : 31:A1054
January 1990 EH Kraut, Neidhart J and MacDonald J."Phase II Trial of Pibenzimol in Advanced Pancreatic Carcinoma: A Southwest Oncology Group Study" . : 9:A504
January 1990 EH Kraut, Neff J, Gochnour D and Grever MR."Immunosuppressive Effects of Pentostatin" .
January 1990 EH Kraut, MR Grever, BA Bouroncle."Long Term Followup of Hairy Cell Leukemia Patients Treated with 2-Deoxycoformycin" .
January 1990 EH Kraut, Bouroncle BA, and Nelson DL."Usefulness of Soluble IL-2 Receptor as a Marker of Disease Activity in Hairy Cell Leukemia" . : 9:A504
January 1991 EH Kraut, Balcerzak SP, Kemmenoe BH and Supko JG."Phase I Clinical Evaluation of Pyrazine Diazohydroxide in Patients with Advanced Solid Tumors" . : 32:A1074
January 1994 Slavik M, Liu PY, EH Kraut, Natale R, Sondak V."Phase II Evaluation of Merbarone in Disseminated Malignant Melanoma" .
January 1994 Subramanian D, EH Kraut, Staubus A, Muller M."Analysis of Topoisomerase I/DNA Covalent Complexes in Peripheral Blood of Patients Administered Topotecan" .
January 1995 EH Kraut, Staubus A, Mayernik D, King G and Balcerzak SP."Phase II Trial of Topotecan in Metastatic Malignant Melanoma" . : 28:204
January 1995 E Kraut, Crowley J, Wade J, Laufman L, Weiss G, Taylor S, Salmon S."Evaluation of Topotecan in Resistant and Relapsing Multiple Myeloma" . : 86(10)(Suppl 1)(#726):185a
January 1996 Koch CA, Archer TP, EH Kraut.."Myocardial Ischemia in a Patient with Chronic refractory Idiopathic Thrombocytopenic Purpura" .
January 1997 EH Kraut, Balcerzak SP, and Young D,."A Phase II Study of Topotecan In Non-Hodgkin’s Lymphoma" . : 15(1):67
January 1998 Chauncey TR, Rankin C, Anderson JE, Godwin JA, Kalaycio M, Moore DF, Petersdorf SH, Shurafa MS, EH Kraut, Head DR, Slovak ML, Willman CL, and Appelbaum FR."A Phase I Dose-Finding Study of Induction Chemotherapy For Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Mitoxantrone (M), Etoposide (E), and The MDR Modulator PSC833" .
January 1999 Thomas JP, Moore TD, EH Kraut, Balcerzak SP."A Phase II Study of CI-980 in Previously Untreated Small-Cell Lung Cancer" .
January 2000 Aguayo A, EH Kraut, Moore D, Hoff P, Wright J, Winn R, Jones D, Pazdur R."Total Oxaliplatin (NSC-266046) Levels in Plasma and Ultrafiltrate in Rats and in Combination with Paclitaxel as Measured by Inductively Coupled Plasma Mass Spectometry" .
January 2001 EH Kraut, Bender J, Clinton S, Jensen R, Balcerzak S, Chan K, Mueller C, Vaswani K, Mantil J, Christian B, Grever M."Phase I Study of SU5416 in Combination with CPT-11 and Cisplatin in Patients with Solid Tumors" .
January 2001 EH Kraut, Bender J, Liu J, Balcerzak S, Jensen R, Chan K, Dambrosio S, Grever M."Phase I Study of Oxaliplatin (NSC 266046) in Combination with Paclitaxel" .
January 2002 Mauer AM, EH Kraut, Rudin CM, Krauss SA, Ansari RH, Hoffman P.C., Saltz L, Vokes, EE."Phase II study of of Oxaliplatin, fluoruracil, and leucovorin in metastatic carcinoma of the esophagus/gastric cardia" .
January 2003 Kuebler JP, Moore T, Pritchard J, EH Kraut.."Phase II Study of CI-958 in patients with Hormone Refractory Prostate Carcinoma" .
January 2003 A.m Mauer, E.H. Kraut, S.A. Krauss, R.H. Ansari, K. Kasza, L. Szeto, E.E. Vokes,."Phase II Trial of Oxaliplatin, Leucovorin, and Fluorouracil in patients with Advanced Carcinoma of the Esophagus" .
January 2004 Ewenstein B, Paul LF, Giangrande PL, Morfini M, Tjonnfjord GE, EH Kraut, Luu H."Evaluation of FEIBA for Prophylaxis in Patients with Inhibitors" . : 10(s3), 53-66
January 2004 Negrier C, Tjonnfjord G, EH Kraut, Giangrande PL, Ewenstein Band the FEIBA Study Group."Efficacy of FEIBA in Surgical and Invasive Procedures" . : 10:174-178
January 2004 Lin TS, Fischer B, Moran M, Lucas D, Shank R, EH Kraut, Farag SS, Lucas M, Colevas AD, Grever MR, Byrd JC."Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab is Active in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma" .
January 2004 Eric Kraut, Sylvia Jordan, Leslie Witkoff and Michael Stanek."Control of Bleeding in Patients with Inhibitors to Factor VIII and IX Undergoing" . : 10:174-178
January 2004 Cataland SP, George JN, EH Kraut, Bourgeois T, Ferketich AK, Kennedy MS, Caligiuri MA, Wu HM."Improved Clinical Outcome and ADAMTS13 Activity Following Cyclosporine Therapy in Patients with TTP" . : 104:243a
January 2005 EH Kraut, Aledort, LM, Arkin, S, Stine, KC, Wong, W-Y."Surgical Procedures in Patients With Inhibitors To Factor VIII: A Case Series" .
January 2005 Eric H. Kraut, Spero R Cataland, M.D., Leslie Witkoff, R.N., Sylvia Jordan, R.N. and William T Gunning, Ph.D."Evaluation of Qualitative Platelet Disorders in patients with Hemophilia" . : 106 (11) 3987
January 2005 S.S Farag, S. Zhang, M. Miller,M. Buckner, E. Kraut, K Chan, C. Eng, J. Byrd, J.E. Dancey, M.R. Grever."Phase II trial of CCI-779 (Temsirolimus) in patients with relapsed or refractory multiple myeloma: Preliminary results" .
January 2005 Kurt P. Leuenerger, M.D., Spero Cataland, M.D., Ming Jin, M.D., Carol Orr, Guido Marcucci, M.D., Eric H. Kraut, M.D., Jaifeng M. Wu, M.D."Distinguishing Antiphospholipid Antibodies from an Acquired Factor Inhibitor: A Novel Laboratory Approach" . : 106: 2150
January 2005 T.S. Lin, B. Fischer, M.E. Moran, R.S. Shank, E. Kraut, P. Porcu, S.S. Farag, K.A. Blum, A.D. Colevas, M.R. Grever, J.C. Byrd."Flavopiridol, Fludarabine and Rituximab (FFR) is an active regimen in indolent B-cell lymphoproliferative disorders and mantle cell lymphoma (MCL)" . : No. 11, abstract 944, p. 278a
January 2005 Subha V. Raman, Md, MS, Orlando P. Simonetti, PhD, Spero R. Cataland, MD, William J. Hicks, MD, Eric H. Kraut, MD.."Myocardial Ischemia without Coronary Artery Obstruction in Patients with Sickle Cell Disease" . : 106(11) 3180
January 2006 Zhiliang Xie, Zhongfa Liu, Lucy Fang, Eric Kraut, Tanios Saab, Xiaohui Wei, Hao Cheng, Duxin Sun, Michael Grever and Kenneth K. Chan."Clinical Pharmcokinetics of the VEGF Kinase Inhibitor SU-5416 in Combination with CPT-11 and Cisplatin in Patients with Solid Tumors using an PII LC-MS/MS Method" .
January 2007 Bryce Kerlin, Spero Cataland, Elizabeth Varga, Eric Kraut and Mark Wurster."Common Clinical Variables Predict Warfarin Maintenance Dose and Therapeutic Resistance" .
January 2007 Kami Perdue, Spero Cataland, Eric H. Kraut, Carol Blanchong, Sarah O’Brien, and Bryce Kerlin."HTRS TERegistry: Offering A Better Understanding Of ThromboEmbolic Disease" .
June 2008 Bekaii-Saab, Kenneth Chan, Stanley Balcerzak, Jing Liu, Percy Ivy, Michael Grever, Eric Kraut.."A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors." . : 3434-3440
August 2008 TS Lin, B Fischer, Blum KA, P Porcu, EH Kraut, RA Baiocchi, S Broering, MR Grever and JC Byrd."Flavopiridol, Fludarabine and Rituximab (FFR) Is Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma" .
Sackey, K., Desai, P., Kraut, E.."Creation of a Patient Data Registry Could Improve Care for Sickle Cell Disease Patients." .


Topotecan on Refractory and Relapsing Myeloma

The Role of Topoisomerase I Inhibitors in Multiple Myeloma�

Evaluation of Thrombocytopenia

Developmental Chemotherapy in multiple myeloma, the search for the magic bullet

Control of Bleeding in Patients with Inhibitors to Factor VIII and IX Undergoing Surgical

Chemotherapy Principles

Hematology Introduction

Myeloproliferitive Disease

Sickle Cell Anemia

Surgical Procedures in Patients With Inhibitors To Factor VIII

Hemolytic Anemia

Hemolytic Anemia

Heme Emergencies Coagulopathies

Hemolytic Anemia

Introduction to Hematology

Hemolytic Anemia



Hematologic Disorders and the Eye

HIT/Use of Argatroban/Platelet Function with Reopro

Hemolytic Anemia

Diagnosis and Management of Hemolytic Anemia

Diagnosis and Management of Hemolytic Anemia

Clinical Bleeding

Sickle Cell


Hematalogic Emergencies

Hemolytic Anemia

Hemolytic Anemia/ Sickle Cell Disease

Benign Hematology



Hemoglobin and Hemoglobinopathies

Disorder of Neutrofil Number and Function

Bleeding Disorders for the Oral Surgeon

Complications of Anticoagulant and Thrombolytic Therapy


Sickle Cell Anemia

Sickle Cell Anemia

Hematologic Emergencies

Hemophilia and vonWillebrand's Disease

Hypercoagulability and Thrombosis.


Sickle cell anemia.


Professional Activities

2006 - present Panel Expert. Net Wellness, Consumer Health Information. Columbus, OH.